Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arix To Nurture Next Generation Biotechs After UK IPO

Executive Summary

The supply of "permanent" capital and the desire to be involved operationally in new life science companies are some of the aims of Arix Bioscience, a UK company aiming to float on the London Stock Exchange, possibly by the end of this month.

You may also be interested in...



Arix Says Latest Equity Raising May Be Last For Some Time As Exit Options Loom

Arix Bioscience's £87m equity raising brings to £250m the amount it has raised for incubating life sciences start-ups – but it might be the last for a while if portfolio 'exits' start generating cash, its CEO tells Scrip.

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.

Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash

Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel